UBX News and Press, Unity Biotechnology Inc. From 03/27/23

2023-03-27 08:32:38 ET Unity Biotechnology ( NASDAQ: UBX ) lost ~48% pre-market Monday after announcing that its lead candidate UBX1325 failed to outperform Regeneron’s ( REGN ) blockbuster eye therapy aflibercept in a Phase 2 trial for wet age-related macular deg...

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline ...

2023-03-15 16:49:11 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q4 Non-GAAP EPS of -$1.00. Cash, cash equivalents and marketable securities totaled $94.8 million as of December 31, 2022 compared with $90.1 million as of December 31, 2021. Operating loss for t...

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 202...

2023-03-05 07:14:56 ET Summary Shares of ophthalmology concern Unity Biotechnology are down some 90% since our last look in March 2021 as a news vacuum following a failed Phase 2 trial in October. That said, the company was able to leverage good interim data from its only clinical...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporat...

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporat...

-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET- -Complete 16- and 24-week safety and efficacy data from phase 2 ENVISION study in wet AMD expected in Q1 2023- SOUTH SAN FRANCISCO, Calif.,...

Unity Biotechnology press release ( NASDAQ: UBX ): Q3 GAAP EPS of -$1.36 misses by $0.30 . The company believes that current cash, cash equivalents, and marketable securities of $103.9M are sufficient to fund operations into the first quarter of 2024. For further...

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Ph...